Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Taina Rosa, Olivia Meyer
07.08.26
Pillsbury advised TJM Labs, the leading pharmacy AI platform automating operational work for pharmacies, on its $75 million Series B funding round. The transaction follows the company’s $10 million Series A and $15 million Series A-1 financings, bringing TJM Labs’ total capital raised to $100 million across three funding rounds in approximately six months.
The Series B was led by Elephant, with additional participation from Arthur Ventures and Updata Partners.
In conjunction with the financing, TJM Labs also announced it is now live in more than 450 pharmacies and has completed the acquisitions of EncoreRx and Pharmesol, both of which Pillsbury also advised on. The acquisitions have expanded the company’s automation and voice capabilities into a single pharmacy-native AI platform.
TJM Labs’ AI agents automate high-volume operational workflows, including prescription intake, data entry, refills, prior authorization support and patient communications, while integrating with the pharmacy systems teams already use. The latest financing and growth milestones underscore the company’s emergence as a leader in pharmacy AI as the market shifts from isolated point solutions to enterprise-scale automation platforms.
To learn more, click here.
The Pillsbury deal team was led by Corporate partner Steven Green and included senior associate Kendy Chan and associate Olivia Fong.